Pembrolizumab + Cisplatin + 5-fluorouracil + oxaliplatin + capecitabine + Placebo for Pembrolizumab
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Stomach Neoplasms
Conditions
Stomach Neoplasms
Trial Timeline
Nov 8, 2018 → Mar 3, 2025
NCT ID
NCT03675737About Pembrolizumab + Cisplatin + 5-fluorouracil + oxaliplatin + capecitabine + Placebo for Pembrolizumab
Pembrolizumab + Cisplatin + 5-fluorouracil + oxaliplatin + capecitabine + Placebo for Pembrolizumab is a phase 3 stage product being developed by Merck for Stomach Neoplasms. The current trial status is completed. This product is registered under clinical trial identifier NCT03675737. Target conditions include Stomach Neoplasms.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03675737 | Phase 3 | Completed |
| NCT04859582 | Phase 3 | Withdrawn |
Competing Products
20 competing products in Stomach Neoplasms